Copyright
©2012 Baishideng.
World J Gastrointest Endosc. Sep 16, 2012; 4(9): 409-413
Published online Sep 16, 2012. doi: 10.4253/wjge.v4.i9.409
Published online Sep 16, 2012. doi: 10.4253/wjge.v4.i9.409
Table 2 Incidence of colorectal cancer presenting symptoms and the distribution of cancer in the two groups of the study n (%)
| Antiplatelet group (n = 98) | Control group (n = 289) | |
| Symptoms | ||
| Anemia | 43 (43.8) | 104 (35.9) |
| Blood loss per rectum | 28 (28.5) | 56 (19.3) |
| Obstruction/perforation | 15 (15.3) | 66 (22.8) |
| Altered bowel habits | 3 (3) | 29 (10) |
| Non-specific symptoms | 4 (4) | 18 (6.2) |
| Screening | 5 (5.1) | 16 (5.5) |
| Distribution | ||
| Right | 42 (42.8) | 116 (40.1) |
| Left | 33 (33.6) | 104 (35.9) |
| Rectum | 23 (23.4) | 69 (23.8) |
- Citation: Symeonidis D, Koukoulis G, Christodoulidis G, Mamaloudis I, Chatzinikolaou I, Tepetes K. Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastrointest Endosc 2012; 4(9): 409-413
- URL: https://www.wjgnet.com/1948-5190/full/v4/i9/409.htm
- DOI: https://dx.doi.org/10.4253/wjge.v4.i9.409